Those cytokines can impair NK cell cytotoxicity and trigger Th1 response which inducing IFN-γ secretion, a possible pathogenic process in patients experiencing the complication.[20] High-dose glucocorticoid, even pulse dose (500–1000 mg/daily for a maximum of 6 cycles) are recommended to treat patients with MAS, and then followed by IL-1 or IL-6 inhibitors. The gene discussed is IFNG; the disease is macrophage activation syndrome.